Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Is there data to support the upfront use of encorafenib and cetuximab in metastatic BRAF V600E-mutated right-sided colon cancer?
Answer from: Medical Oncologist at Academic Institution
There is an ongoing trial (BREAKWATER) that will answer this but not yet.
Sign In
or
Register
to read more
22108
Related Questions
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
What is the optimal systemic therapy for metastatic Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED)?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
What are your top takeaways in GI Cancers from ASCO 2025?
Why does NCCN still not recommend using circulating tumor DNA to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?
After neoadjuvant Nivolumab/Ipilimumab x4, do you offer adjuvant Nivolumab in the adjuvant setting for oligometastatic MSI-high colon cancer in a patient who achieved CR?
How do you approach an isolated metastasis to left supraclavicular node in rectal cancer treated with TNT with FOLFOX regimen followed by long course radiation?
What is the appropriate monitoring for an incidental low-grade rectal neuroendocrine tumor resected endoscopically with positive margins?
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
Is there role of HER2 directed therapy in adjuvant treatment of colon adenocarcinoma for tumors that are HER2 3+ by IHC?